Drug-Induced Enteric Neuropathy: Recognition and Prevention

Abstract

Drug-induced enteric neuropathy represents a significant but often underrecognized complication of pharmacotherapy, affecting gastrointestinal motility and function through damage to the enteric nervous system. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management of drug-induced enteric neuropathy, highlighting both established and emerging therapies. Emphasis is placed on the practical implications for clinicians, including strategies for early recognition, prevention, and evidence-based management in line with recent guidelines.

Introduction

The enteric nervous system (ENS), sometimes referred to as the "second brain," orchestrates the complex regulation of gastrointestinal motility, secretion, and blood flow. Drug-induced enteric neuropathy is a clinically significant entity wherein pharmacologic agents disrupt the normal ENS function, resulting in a spectrum of gastrointestinal symptoms and complications. Given the expanding pharmacopeia and increased polypharmacy in aging populations, clinicians must remain vigilant for this iatrogenic disorder. This article reviews the current understanding of drug-induced enteric neuropathy, providing clinicians with up-to-date, evidence-based insights for optimal patient care.

Epidemiology / Disease Burden

The precise incidence and prevalence of drug-induced enteric neuropathy remain uncertain, partly due to challenges in diagnosis and underreporting. However, studies estimate that up to 30% of patients on chronic opioid therapy develop opioid-induced bowel dysfunction, a subset of enteric neuropathy. Other drugs, including chemotherapeutic agents, antipsychotics, and certain antibiotics, contribute to the burden. Elderly patients, those with multiple comorbidities, and individuals on polypharmacy are disproportionately affected. The clinical and economic consequences are substantial, as enteric neuropathy often leads to recurrent hospitalizations, reduced quality of life, and increased healthcare utilization.

Pathophysiology

Drug-induced enteric neuropathy arises from direct neurotoxic effects or secondary mechanisms that impair ENS integrity and function. Opioids, for example, inhibit acetylcholine release from enteric neurons via μ-opioid receptor activation, thereby reducing peristalsis and secretory activity. Chemotherapeutic agents such as vincristine and cisplatin cause axonal degeneration and neuronal apoptosis by disrupting microtubule function or generating oxidative stress. Certain antibiotics, notably metronidazole and nitrofurantoin, are implicated in mitochondrial injury within enteric neurons. Disruption of neurotransmitter balance, impaired neurogenesis, and inflammatory changes further contribute to ENS dysfunction. Importantly, cumulative dose, duration of therapy, and individual susceptibility modulate the risk and severity of neuropathic changes.

Risk Factors

Risk factors for drug-induced enteric neuropathy include advanced age, pre-existing gastrointestinal disorders (such as irritable bowel syndrome or inflammatory bowel disease), diabetes mellitus, chronic renal or hepatic dysfunction, and genetic polymorphisms affecting drug metabolism (e.g., CYP450 variants). Polypharmacy and high cumulative doses of neurotoxic agents further elevate risk. Notably, oncology patients receiving combination chemotherapeutic regimens and individuals on long-term opioid therapy are especially susceptible. A family history of neuropathic disorders or previous episodes of drug-induced neuropathy may also predispose to recurrence upon re-exposure.

Clinical Features

Clinical manifestations of drug-induced enteric neuropathy are diverse, often mimicking primary gastrointestinal motility disorders. Symptoms range from mild bloating and abdominal discomfort to severe, refractory constipation, pseudo-obstruction, or even intestinal failure. Patients may also report nausea, vomiting, diarrhea, early satiety, and weight loss. In severe cases, complications such as bacterial overgrowth, malnutrition, and sepsis may ensue. The temporal relationship between drug initiation and symptom onset, along with the exclusion of alternative etiologies, is critical for diagnosis. A high index of suspicion is warranted in patients with new or worsening gastrointestinal symptoms following the introduction of neurotoxic medications.

Diagnosis

Diagnosis of drug-induced enteric neuropathy is primarily clinical, supported by a thorough medication history and exclusion of other causes. Objective assessment may include gastrointestinal transit studies, antroduodenal manometry, and wireless motility capsule testing to document dysmotility. Histopathological examination of full-thickness intestinal biopsies, though rarely performed, may reveal neuronal loss, axonal swelling, or inflammatory infiltrates. Ancillary investigations—such as serum markers of inflammation, metabolic panels, and imaging—help rule out structural or metabolic causes. Multidisciplinary collaboration with gastroenterology, pharmacy, and neurology is often beneficial in complex cases.

Treatment & Management

The cornerstone of management is early recognition and prompt discontinuation or dose reduction of the offending agent whenever feasible. Symptomatic therapies include prokinetic agents (e.g., prucalopride, metoclopramide), stool softeners, and laxatives for constipation-predominant presentations. In opioid-induced cases, peripherally acting μ-opioid receptor antagonists (PAMORAs) such as methylnaltrexone and naloxegol offer targeted relief without compromising analgesia. Nutritional support, including enteral or parenteral nutrition, may be required in severe or refractory cases. Patient education regarding medication risks and early symptom reporting is essential for prevention and timely intervention.

Recent Advances / Emerging Therapies

Emerging therapies focusing on neuroprotection and neuroregeneration hold promise for drug-induced enteric neuropathy. Trials investigating the role of neurotrophic factors, antioxidants (such as alpha-lipoic acid), and gut microbiota modulation through probiotics or fecal microbiota transplantation are underway. Advances in precision medicine, including pharmacogenomic screening for susceptibility alleles, may facilitate individualized risk stratification and safer prescribing. Novel prokinetic agents and ENS-targeted therapies are being developed, aiming to restore normal gut motility with fewer adverse effects. Ongoing research into ENS plasticity and regenerative capacity may eventually yield disease-modifying interventions.

Guideline Recommendations

Recent clinical guidelines advocate for judicious use of neurotoxic drugs, especially in high-risk populations. Stepwise approaches include baseline assessment of gastrointestinal function, regular monitoring for new or worsening symptoms, and routine medication review to minimize unnecessary polypharmacy. For patients on chronic opioids, guidelines recommend early consideration of non-opioid analgesics, use of PAMORAs when indicated, and multidisciplinary management of opioid-induced bowel dysfunction. Oncology guidelines emphasize pre-treatment counseling and dose adjustments for patients developing gastrointestinal symptoms during chemotherapy. Interdisciplinary collaboration and patient education are recurrent themes across recommendations.

Conclusion

Drug-induced enteric neuropathy is an important and potentially preventable complication of modern pharmacotherapy. Clinicians must maintain a high index of suspicion, particularly in at-risk populations and those receiving known neurotoxic agents. Early recognition, risk stratification, and proactive management are essential to minimizing morbidity and optimizing patient outcomes. Advances in diagnostic modalities, personalized medicine, and emerging therapeutics offer hope for improved prevention and treatment. Ongoing education, vigilant prescribing, and interdisciplinary care will remain central to effective recognition and prevention of this challenging condition.